[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-intrahepatic-cholangiocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-intrahepatic-cholangiocarcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100651876","phase-2-testing-the-addition-of-ivonescimab-combined-with-standard-chemotherapy-compared-to-the-usual-chemotherapy-and-immunotherapy-treatment-for-patients-with-advanced-biliary-tract-cancer-100651876",false,"NCT07765433","Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer","A Phase II\u002FIII Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer","Inclusion Criteria:\n\n* Patient must be ≥ 18 years of age\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Patient must have histologically or cytologically confirmed adenocarcinoma of the biliary tract including cholangiocarcinoma (intrahepatic or extrahepatic) or gallbladder carcinoma\n* Patient must not have a diagnosis of ampullary cancer\n* Patient must have documented metastatic or locally advanced unresectable disease on CT or MR imaging\n* Patient must have measurable disease as documented on CT or MRI imaging done within 28 days prior to randomization\n* Patient must not have received prior systemic therapy for current metastatic or locally advanced biliary tract cancer\n\n  * NOTE: Patients who have previously received adjuvant\u002Fneoadjuvant chemotherapy and\u002For radiotherapy for curative intent non-metastatic disease are eligible if they developed recurrent disease \\> 6 months after completion of adjuvant therapy\u002Fradiotherapy\n* Patient must not be on any systemic immunosuppressant therapy other than inhaled steroids, intranasal steroids, topical steroids or systemic steroids up to 10mg prednisone equivalent\n* Patient must not have received a live attenuated vaccine within 30 days prior to randomization. Patients must also not receive a live attenuated vaccine while on protocol treatment or up to 30 days after the last dose of protocol treatment\n* Patient must have no contraindication to VEGF inhibitor therapy\n* Patient must not have significant vascular disease (i.e., aortic aneurysm surgical repair or peripheral arterial thrombosis) within 6 months prior to randomization\n* Patient must not have inadequately controlled arterial hypertension (systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\[BP\\] \\> 100 mmHg). Anti-hypertensive therapy to achieve these parameters is allowed\n* Patient must not have experienced a clinically significant bleeding event within 6 months prior to randomization\n* Patient must not have experienced gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, or intraabdominal abscess\n* Patient must not have had surgery within 30 days prior to randomization\n* Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used\n\n  * All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy\n  * A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue contraceptive measures for 6 months after the last dose of protocol treatment, with the exception of cisplatin requiring 14 months for female patients and 11 months for male patients\n* Patient must not nurse infants for 4 months after the last dose of pembrolizumab, 3 months after the last dose of durvalumab or ivonescimab and for four weeks after the last dose of cisplatin\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible\n* Hemoglobin ≥ 9.0 g\u002FdL (must be obtained ≤ 7 days prior to randomization)\n* Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm\\^3 (must be obtained ≤ 7 days prior to randomization)\n* Platelet count ≥ 100,000\u002Fmm\\^3 (must be obtained ≤ 7 days prior to randomization)\n* Bilirubin ≤ 2.5 x institutional upper limit of normal (ULN) (must be obtained ≤ 7 days prior to randomization). Patients with Gilbert's syndrome must have a direct bilirubin \\\u003C 1.5 mg\u002FdL\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \\[SGPT\\]) ≤ 2.5 × institutional ULN (must be obtained ≤ 7 days prior to randomization). For patients with liver metastases, AST and ALT ≤ 5 x ULN\n* Creatinine clearance (CrCI) \\> 50ml\u002Fmin or calculated CrCI \\> 50ml\u002Fmin as determined by Cockcroft-Gault (using actual body weight) Cockcroft-Gault Formula (must be obtained ≤ 7 days prior to randomization)\n* Urine dipstick for proteinuria \\\u003C 2+ or 24 hour urine protein \\\u003C 1.0 g (within 7 days prior to initiation of study treatment)\n* Prothrombin time (PT) or international normalized ratio (INR) and partial thromboplastin time (PTT) ≤ 1.5 X ULN (must be obtained ≤ 7 days prior to randomization). This applies only to patients who are not on therapeutic anti-coagulation. Patients receiving therapeutic anti-coagulation are eligible if on stable dose\n* Patient must not have National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade \\> 2 peripheral neuropathy at the time of randomization\n* Patient must not have a history of allogeneic organ transplantation\n* Patient must not have prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease such as colitis or Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (i.e.: granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.). The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia\n  * Patients with hypothyroidism (i.e.: following Hashimoto syndrome) stable on hormone replacement\n  * Any chronic skin condition that does not require systemic therapy\n  * Patients without an active disease in the last 5 years\n  * Patients with celiac disease controlled by diet alone\n  * Patients with insulin dependent diabetes\n* Patient must not have uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase the risk of incurring AEs, or compromise the ability of the patient to give written informed consent\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to randomization are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2 or better","ALL","18 Years",{"count":19,"type":20},336,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This phase II\u002FIII trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating patients with biliary tract cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivonescimab is a bispecific antibody that is directed against both the programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) protein. By targeting PD-1, ivonescimab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. By targeting VEGF, ivonescimab may help stop the formation of blood vessels that bring oxygen and nutrients to tumor. Adding ivonescimab to standard chemotherapy may work better than usual chemotherapy and immunotherapy in lowering the chance of advanced biliary tract cancer growing or spreading.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Locally Advanced Biliary Tract Adenocarcinoma","Locally Advanced Extrahepatic Cholangiocarcinoma","Locally Advanced Intrahepatic Cholangiocarcinoma","Locally Advanced Unresectable Gallbladder Adenocarcinoma","Metastatic Biliary Tract Adenocarcinoma","Metastatic Extrahepatic Cholangiocarcinoma","Metastatic Gallbladder Adenocarcinoma","Metastatic Intrahepatic Cholangiocarcinoma","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Biliary Tract Adenocarcinoma","Unresectable Extrahepatic Cholangiocarcinoma","Unresectable Intrahepatic Cholangiocarcinoma","NOT_YET_RECRUITING","2026-08-13",{"date":45,"type":46},"2026-08-14","ACTUAL",{"date":48,"type":20},"2027-01-11",{"date":50,"type":20},"2029-12-31",{"name":52,"class":53},"ECOG-ACRIN Cancer Research Group","NETWORK",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100520599","phase-1-radioembolization-with-tremelimumab-and-durvalumab-for-locally-advanced-unresectable-or-oligo-metastatic-intrahepatic-cholangiocarcinoma-100520599","NCT06058663","Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma","Phase 1 Trial of Safety and Preliminary Efficacy of Segmental Ablative Radioembolization in Combination With Tremelimumab Plus Durvalumab (MEDI4736) in Patients With Unresectable, or Oligo-Metastatic Cholangiocarcinoma Who Are Not Candidates for Curative Therapy (RAIDEN Trial)","Inclusion Criteria:\n\n* Age \\>= 18 years with body weight \\> 30 kg\n* Histologically or cytologically confirmed, locally advanced intrahepatic cholangiocarcinoma that is not amenable to resection, transplantation, or thermal ablation. Oligometastatic intrahepatic cholangiocarcinoma is also eligible. Specifically, such patients must have EITHER =\\\u003C 3 malignant extrahepatic lymph nodes (short axis diameter \\>= 3cm) OR metastatic lesions in one organ other than liver (if only single lesion is present diameter MUST be \\\u003C 3cm, if up to 3 lesions in one organ each lesion MUST be =\\\u003C 1cm)\n* Measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Hemoglobin \\>= 9.0 g\u002FdL (=\\\u003C 14 days prior to registration)\n* Absolute neutrophil count (ANC) \\>= 1000\u002Fmm\\^3 (=\\\u003C 14 days prior to registration)\n* Platelet count \\>= 75,000\u002Fmm\\^3 (=\\\u003C 14 days prior to registration)\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) (patients with known Gilbert disease who have serum bilirubin level 3 x ULN may be enrolled) (=\\\u003C 14 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\\\u003C 5 x ULN (=\\\u003C 14 days prior to registration)\n* Calculated creatinine clearance \\>= 40 ml\u002Fmin using the Cockcroft- Gault formula or measured creatinine clearance \\> 40 ml\u002Fmin (=\\\u003C 14 days prior to registration)\n* International normalized ratio (INR) =\\\u003C 1.6. Note: INR prolongation due\n\n  * Anticoagulation (INR \\>= 2.0 but =\\\u003C 3.0)) for prophylaxis in patients without liver cirrhosis could be exception\n* Adequate hepatic function Child Pugh A and albumin-bilirubin (ALBI) 1 or 2\n* Patients with concurrent hepatitis B (HBV) or hepatitis C virus (HCV) infection should meet the following criteria:\n\n  * Patient with HBV or should be monitored for viral levels during study participation\n  * Patient with detectable hepatitis B surface antigen (HBsAg) or detectable HBV DNA should have HBV DNA \\\u003C 100 IU\u002Fml and should be managed per local guidelines\n  * Controlled hepatitis B subjects will be allowed if they have started treatment prior to or by the time point of enrollment into the study and treatment is continued during study participation and for \\>= 6 months after end of study treatment\n  * Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Negative urine pregnancy test done prior =\\\u003C 7 days registration, for persons of childbearing potential only\n\n  * NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n\nExclusion Criteria:\n\n* Concurrent enrollment in another clinical study, unless it is an observational clinical study or during the follow up period of an interventional study\n* Surgery =\\\u003C 28 days prior to registration\n* Chemotherapy =\\\u003C 4 weeks prior to registration\n* History of \\> 1 prior systemic therapy for cholangiocarcinoma not including that in the adjuvant setting. Patients who progressed during or =\\\u003C 6 months from completion of adjuvant therapy are excluded\n* Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade \\>= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\n\n  * Patients with grade \\>= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician\n  * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the study physician\n  * History of previous locoregional therapy\n  * Previous use of therapeutic cancer vaccines\n* Unstable liver function and\u002F or a change in Child Pugh score during screening\n\n  * Child Pugh B or greater\n  * ALBI grade \\> 2\n  * Model for End-Stage Liver Disease (MELD) \\> 10\n* Patient is unable to undergo mapping angiography or mapping angiography demonstrates tumor blood supply that does not lend itself to transarterial therapy\n* A lung shunt fraction greater than 30 Gy within a single session, or cumulative does greater than 50Gy\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Active or uncontrolled autoimmune or inflammatory disorders (including Inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, granulomatosis with polyangiitis, sarcoidosis, Grave's disease)\n* History of another primary malignancy except for:\n\n  * Malignancy treated with curative intent and with no known active disease \\>= 5 years prior to registration and of low potential of recurrence\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing uncontrolled infections including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis (TB) testing in line with local practice), human immunodeficiency virus (HIV), hepatitis B and hepatitis C\n  * Serious chronic gastrointestinal condition associated with diarrhea\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris, cardiac arrhythmia and uncontrolled hypertension\n  * Chronic pulmonary disease including interstitial lung disease requiring oxygen\n  * Psychiatric illness\u002Fsocial situations limiting compliance that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent\n  * Uncontrolled hypertension\n* History of leptomeningeal carcinomatosis\n* History of allogeneic transplantation\n* Current or prior use of immunosuppressive medication \\\u003C 14 days before registration. The following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical steroids, or local steroid injections\n  * Systemic corticosteroids at physiologic doses not to exceed 10mg\u002Fday of\n  * Prednisone or its equivalent\n* Known allergy or hypersensitivity to durvalumab and tremelimumab or any of the constituents of the products\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Pregnant or lactating female\n* Life expectancy \\\u003C 3 months\n* Intolerance to contrast agents that is refractory to medical management\n* Any other condition which the investigator believes would make participation in the study not acceptable\n* History of primary immunodeficiency\n* Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts\n* Receipt of live attenuated vaccine \\\u003C 30 days prior to registration and without need to receive any live attenuated vaccines during study conduct and for up to 30 days after end of durvalumab treatment or 90 days after end of tremelimumab treatment respectively\n* Prior immunotherapy such as durvalumab or pembrolizumab is allowed as long as patient does not have progressive disease on it",{"count":62,"type":20},16,[64],"PHASE1","This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in treating patients with intrahepatic cholangiocarcinoma (cancer of the bile ducts in the liver) that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable) who are not candidates for curative therapy or that has spread from where it first started (primary side) to multiple other places in the body (oligo-metastatic). Cholangiocarcinoma is a rare but aggressive cancer with limited curative options outside of surgery. Immunotherapy has shown modest benefit in hepatobiliary (liver, bile ducts, and gallbladder) cancers including cholangiocarcinoma. Radioembolization is a type of radiation therapy used to treat liver cancer that is advanced or has come back where tiny beads that hold the radioactive substance (radioisotope) yttrium Y90 are injected into or near the hepatic artery (the main blood vessel that carries blood to the liver). The beads collect in the tumor and the Y90 gives off radiation. This destroys the blood vessels that the tumor needs to grow and kills the tumor cells. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving Y90 radioembolization in combination with tremelimumab and durvalumab immunotherapy may be safe and beneficial in treating patients with locally advanced, unresectable or oligo-metastatic intrahepatic cholangiocarcinoma who are not candidates for curative therapy.",[29,67,36,38,41],"Oligometastatic Intrahepatic Cholangiocarcinoma","RECRUITING","2026-05-11",{"date":71,"type":46},"2026-05-13",{"date":73,"type":46},"2024-06-06",{"date":75,"type":20},"2028-11-30",{"name":77,"class":78},"Mayo Clinic","OTHER",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":79},"100586080","liver-transplantation-for-locally-advanced-intrahepatic-cholangiocarcinoma-after-sirt-and-chemotherapy-100586080","NCT06910722","Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy","Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After Selective Internal Radiotherapy With Labeled Yttrium and Chemotherapy: a Phase 2 Study","RIS-TH","Inclusion Criteria:\n\n* Patient aged 18 to 65\n* With histologically documented intrahepatic cholangiocarcinoma (primary diagnosis):\n\n  * Uni or pauci nodular (≤ 5 lesions (all lesions are counted, even those less than 1 cm))\n  * Without extrahepatic or lymph node involvement\n  * Technically unresectable R0 according to an expert panel\n* Tumor target \\> 2 cm\n* WHO 0-1\n* free and informed consent signed\n* highly effective contraception for men and women of childbearing age during study participation up to 2 years post TH\n\nExclusion Criteria:\n\n* Extrahepatic, vesicular or perihilar cholangiocarcinoma\n* Tumor infiltration of more than 50% of the liver\n* Mixed cholangiocarcinoma, hepatocellular carcinoma, fibrolamellar carcinoma\n* Previous treatment for CCI\n* Cirrhosis ≥ Child B7\n* Chronic alcoholism\n* Uncontrolled chronic active infections (patients with HBV, HCV or HDV infections may be included if infections are controlled)\n* Stage III A, IIIB, IV and V chronic renal failure (glomerular filtration rate 59 ml\u002Fmin)\n* Contraindications to liver transplant\n\n  * Severe untreatable conditions\n  * Recent history (less than 5 years) of cancer\n  * severe comorbidities\n  * Psychiatric or psychological disorders\n* Pregnant or breast-feeding women\n* Patient under guardianship\n* Not affiliated to a Health care system\n* Participating in another interventional study or within the exclusion period of a previous study involving the human body","65 Years",{"count":90,"type":20},36,[92],"NA","The study hypothesis is that liver transplantation after selective internal radiation therapy (SIRT) and chemotherapy would improve 3-year overall survival in patients with locally advanced (unresectable but non-metastatic) intrahepatic cholangiocarcinoma.\n\nIt is planned to include 36 patients with locally advanced intrahepatic cholangiocarcinoma, not eligible for initial surgery and without metastases. Participants will be recruited from care facilities in France.",[95,29],"Intrahepatic Cholangiocarcinoma",[97,98,99],"liver transplantation","locally advanced intrahepatic cholangiocarcinoma","selective internal radiation therapy","2026-04-02",{"date":102,"type":46},"2026-04-06",{"date":104,"type":46},"2025-08-28",{"date":106,"type":20},"2034-10-01",{"name":108,"class":78},"Assistance Publique - Hôpitaux de Paris"]